Tiny bug may warn of big infection in kids with cystic fibrosis

NCT ID NCT03947957

Ongoing Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 70 infants with cystic fibrosis to see if a specific germ (Porphyromonas catoniae) found in their body at 12 months old can predict whether they will get a serious lung infection with Pseudomonas aeruginosa by age 3. Researchers collect sputum, stool, and blood samples over time. The goal is to find a warning sign that could help doctors act sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify children with cystic fibrosis at highest risk for Pseudomonas infection, allowing earlier monitoring or intervention.
What could go wrong: This is an observational study, not a treatment trial. It only looks for a link between a biomarker and later infection; it does not test any therapy. The results may not lead to direct clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

CHRU Angers

Angers, France
CHRU Nantes

Nantes, France
CHRU Rennes

Rennes, France
CHRU de Tours

Tours, France
CHU Grenoble

Grenoble, France
Centre de Perharidy

Roscoff, France
Hôpital Charles Nicolle

Rouen, France
Hôpital Femme-Mère-Enfant Lyon

Lyon, France
Hôpital Necker

Paris, France
Hôpital Trousseau

Paris, France
Hôpital des Enfants Bordeaux

Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.